Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Switzerland | Healthcare | Pharmaceuticals | CHF 719.21B | 74.3x | 0.73 | CHF 745 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 231.92B | 28x | -1 | CHF 308.20 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.2% Downside | Upgrade to Pro+ | |
Roche Holding Participation | Switzerland | Healthcare | Pharmaceuticals | CHF 231.92B | 28x | -1 | CHF 289 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1% Upside | Upgrade to Pro+ | |
Novartis | Switzerland | Healthcare | Pharmaceuticals | CHF 191.25B | 18.4x | -1.01 | CHF 97.14 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | Switzerland | Healthcare | Pharmaceuticals | CHF 191.25B | 18.4x | -1.01 | CHF 96.83 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.1% Upside | Upgrade to Pro+ | |
Sandoz | Switzerland | Healthcare | Pharmaceuticals | CHF 19.33B | -2,379.2x | 26.23 | CHF 44.07 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2% Downside | Upgrade to Pro+ | |
Siegfried Holding Ltd | Switzerland | Healthcare | Pharmaceuticals | CHF 4.49B | 34.6x | -2.4 | CHF 1,046 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.9% Upside | Upgrade to Pro+ | |
Galenica Sante | Switzerland | Healthcare | Pharmaceuticals | CHF 4.08B | 23x | -0.71 | CHF 81.80 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.3% Downside | Upgrade to Pro+ | |
Dottikon Es Holding AG | Switzerland | Healthcare | Pharmaceuticals | CHF 2.95B | 38.8x | -3.15 | CHF 213.50 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Joincare Pharmaceutical DRC | Switzerland | Healthcare | Pharmaceuticals | CHF 2.57B | 14.7x | 4.71 | CHF 7.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
COSMO Pharma | Switzerland | Healthcare | Pharmaceuticals | CHF 1.01B | 15.6x | 0.03 | CHF 63 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.9% Upside | Upgrade to Pro+ | |
PolyPeptide Group AG | Switzerland | Healthcare | Pharmaceuticals | CHF 773.47M | -31.4x | -1.32 | CHF 23.45 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Santhera Pharmaceuticals Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 208.08M | 2.8x | 0.02 | CHF 16.52 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Curatis Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 61.14M | -0.1x | CHF 12.60 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Spexis | Switzerland | Healthcare | Pharmaceuticals | CHF 811.97K | -0.2x | CHF 0.010 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |